EU/3/16/1814: Orphan designation for the treatment of malignant mesothelioma

Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin

Overview

On 12 January 2017, orphan designation (EU/3/16/1814) was granted by the European Commission to TREAT U, S.A., Portugal, for doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin for the treatment of malignant mesothelioma.

Key facts

Active substance
Doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31-aminoacid peptide targeting nucleolin
Medicine name
-
Intended use
Treatment of malignant mesothelioma
Orphan designation status
Positive
EU designation number
EU/3/16/1814
Date of designation
12/01/2017
Sponsor
TREAT U, S.A.
Parque Industrial de Taveiro, lote 44
3045-508 Coimbra
Portugal
Tel. +351 239 800 360
E-mail: info@treatu.pt

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating